艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性比较

艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性比较
徐冬;吕晓伟;崔鹏;马尚民
【期刊名称】《疑难病杂志》
【年(卷),期】2017(16)9
【摘要】目的比较艾拉莫德与羟氯喹治疗干燥综合征患者的效果及安全性.方法
选取2016年1月-2017年1月山东省淄博市第一医院风湿免疫科收治的干燥综
合征患者94例作为研究对象,按照随机数字表法分为对照组和观察组各47例.对照组:甲泼尼龙片8 mg,晨起顿服,1次/d,硫酸羟氯喹片0.2 g,2次/d.观察组:甲泼尼龙8 mg,晨起顿服,1次/d;艾拉莫德片25 mg口服,2次/d.2组疗程均 3个月.比较2
组患者临床效果、红细胞沉降率(ESR)、免疫球蛋白G(IgG)、类风湿因子(RF)、血小板计数(PLT)、干燥综合征疾病活动指数(ESSDAI)评分、干燥综合征患者报告指
数(ESSPRI)评分、Schirmeri试验及唾液流率变化,并记录2组患者不良反应.结果
观察组总有效率为93.6%,高于对照组的76.6%(χ2=5.371, P =0.020);2组各项生
化指标及评分均较治疗前显著改善( P <0.05),观察组ESR、IgG、RF、ESSDAI、ESSPRI评分低于对照组,PLT计数、Schirmeri试验、唾液流率高于对照组
(t=3.115、6.921、3.239、5.346、10.011、4.368、6.263、5.819, P <0.01).2
组患者治疗过程发生胃肠道不适、肝功能异常、皮疹、瘙痒、白细胞降低等不良反应发生率比较,差异均无统计学意义(χ2=0.255、2.272、0.435、0.781、2.122, P> 0.05).结论艾拉莫德较羟氯喹治疗干燥综合征患者效果更确切,可有效降低血清B
淋巴细胞活性,且安全可靠.%Objective To compare the efficacy and safety of iguratimod and hydroxychloroquine in the treatment of Sjogren's syndrome.Methods Ninety-four cases of patients with Sjogren's syndrome
were selected, who were treated in department of rheumatology of the First Hospital of Zibo City from January 2016 to January 2017, they were divided into the observation group (47 cases) and control group (47 cases).The patients of control group were treated with methylprednisolone tablets (8 mg / time, morning meal, 1 time / d) and hydroxychloroquinoline sulfate (0.2 g / time, 2 times / d).The patients of observation group were treated with methylprednisolone (8 mg / time, morning meal, 1 time / d) and alamomide tablets (oral, 25 mg / time, 2 times / d).The patients of 2 groups were all treated for 3 pare the clinical effect, adverse reactions and changes of the ESR, IgG, RF, PLT, ESSDAI score, ESSPRI score, Schirmeri test and saliva flow rate of two groups.Results After treatment, the patients of the observation group got
a total effective rate of 93.6%, which was significantly better than the 76.6% of the control group (χ2=5.371, P =0.020);The ESR, IgG, RF, ESSDAI, ESSPRI scores of the observation group were significantly lower than those of the control group, and the PLT counts, Schirmeri test, saliva flow rate of the observation group were significantly higher than those of the control group (t =3.115、6.921、3.239、5.346、10.011、4.368、6.263、5.819;P
<0.01);There were gastrointestinal discomfort, abnormal liver function, rash, itching, leukopenia and other adverse reactions occurred in both two groups, but there were no statistically significant between the two groups (χ2=0.255、2.272、0.435、0.781、2.122, P >0.05).Conclusion Compared with hydroxychloroquine, iguratimod for treating Sjogren's syndrome can achieve more precise results, effectively reduce the activity of serum B
lymphocyte, and it is safe and reliable, which makes it worthy of clinical application.
【总页数】4页(P915-918)
【作者】徐冬;吕晓伟;崔鹏;马尚民
【作者单位】255200 山东省淄博市第一医院风湿免疫科;255200 山东省淄博市第一医院血液内科;255200 山东省淄博市第一医院风湿免疫科
【正文语种】中文
【相关文献】
1.艾拉莫德联合羟氯喹治疗干燥综合征患者的疗效及对B细胞表面分子表达的影响[J], 吉健华;成洁
2.艾拉莫德与羟氯喹治疗干燥综合征疗效及安全性比较 [J], 赵建青
3.艾拉莫德与羟氯喹治疗干燥综合征的疗效及安全性 [J], 魏冬慧
4.艾拉莫德与羟氯喹治疗干燥综合征的疗效及安全性 [J], 魏冬慧
5.艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性 [J], 罗绮雯;郭冬梅;余旸弢;林嘉鸿
因版权原因，仅展示原文概要，查看原文内容请购买。